בליאומיצין PFI

Pays: Israël

Langue: hébreu

Source: Ministry of Health

Ingrédients actifs:

BLEOMYCIN SULFATE

Disponible depuis:

MEGAPHARM LTD

Code ATC:

L01DC01

forme pharmaceutique:

אבקה להכנת תמיסה לזריקה

Composition:

BLEOMYCIN SULFATE 15000 IU/VIAL

Mode d'administration:

לתוך קרום הריאה, תוך-עורקי, תוך-ורידי, תת-עורי, תוך-שרירי, לתוך בקע

Type d'ordonnance:

מרשם נדרש

Fabriqué par:

BAXTER ONCOLOGY GmbH, GERMANY

Groupe thérapeutique:

BLEOMYCIN

Domaine thérapeutique:

BLEOMYCIN

indications thérapeutiques:

Bleomycin is useful in the management of the following neoplasms: Squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesaphagus, cervix, vagina, penis and skin. Well differentiated tumors usually respond better than anaplastic ones.Hodgkin's disease and other malignant lymphomas, including mycosis fungoides. Testicular carcinoma (seminoma and no seminoma) .Malignant effusions of serous cavities (intrapleural and intraperitoneal).Secondary indications in which bleomycin has been shown to be of some value include metastatic malignant melanoma, carcinoma of the thyroid lung and bladder. Local treatment of refractory warts. Bleomycin can be used as a single agent, but is generally used in combination with other cytotoxics and/or with radiation therapy.

Date de l'autorisation:

2020-09-30